keyword
MENU ▼
Read by QxMD icon Read
search

Antiemetics

keyword
https://www.readbyqxmd.com/read/27915445/granisetron-extended-release-injection-a-review-in-chemotherapy-induced-nausea-and-vomiting
#1
Emma D Deeks
An extended-release (ER) subcutaneously injectable formulation of the first-generation 5-HT3 receptor antagonist granisetron is now available in the USA (Sustol(®)), where it is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy regimens in adults. Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drug-delivery system to allow prolonged granisetron release...
December 3, 2016: Drugs
https://www.readbyqxmd.com/read/27909835/breakthrough-chemotherapy-induced-nausea-and-vomiting-report-of-a-nationwide-survey-by-the-cinv-study-group-of-japan
#2
Kazuo Tamura, Keisuke Aiba, Toshiaki Saeki, Yoichi Nakanishi, Toshiharu Kamura, Hideo Baba, Kazuhiro Yoshida, Nobuyuki Yamamoto, Yuko Kitagawa, Yoshihiko Maehara, Mototsugu Shimokawa, Koichi Hirata, Masaki Kitajima
BACKGROUND: We conducted a nationwide survey on chemotherapy-induced nausea and vomiting (CINV) in Japan and demonstrated good compliance with Japanese CINV guidelines, resulting in good control of vomiting. However, almost half the patients experienced breakthrough CINV. We analyzed the survey results in relationship to the management of patients with breakthrough CINV. METHODS: This multicenter, prospective, observational study analyzed data for 1910 patients in Japan scheduled for moderately or highly emetogenic chemotherapy (MEC and HEC, respectively)...
December 1, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27902493/intravenous-amisulpride-for-the-prevention-of-postoperative-nausea-and-vomiting-two-concurrent-randomized-double-blind-placebo-controlled-trials
#3
Tong J Gan, Peter Kranke, Harold S Minkowitz, Sergio D Bergese, Johann Motsch, Leopold Eberhart, David G Leiman, Timothy I Melson, Dominique Chassard, Anthony L Kovac, Keith A Candiotti, Gabriel Fox, Pierre Diemunsch
BACKGROUND: Two essentially identical, randomized, double-blind, placebo-controlled, parallel-group phase III studies evaluated the efficacy of intravenous amisulpride, a dopamine D2/D3 antagonist, in the prevention of postoperative nausea and vomiting in adult surgical patients. METHODS: Adult inpatients undergoing elective surgery during general anesthesia and having at least two of the four Apfel risk factors for postoperative nausea and vomiting were enrolled at 9 U...
November 30, 2016: Anesthesiology
https://www.readbyqxmd.com/read/27900562/special-section-mascc-esmo-antiemetic-guidelines-special-guest-editors-alex-molasiotis-matti-aapro-jorn-herrstedt-richard-gralla-fausto-roila
#4
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27896642/seom-clinical-guideline-update-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-2016
#5
R de Las Peñas, A Blasco, J De Castro, Y Escobar, R García-Campelo, A Gúrpide, R Lopez-Lopez, M Majem, C A Rodríguez, J A Virizuela
Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients...
November 28, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27894202/rolapitant-for-the-prevention-of-delayed-nausea-and-vomiting-over-initial-and-repeat-courses-of-emetogenic-chemotherapy
#6
Bernardo Rapoport, Ronwyn van Eeden, Teresa Smit
Introduction Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. Although sustained antiemetic control across repeated chemotherapy cycles is important for cancer treatment continuation, few studies have investigated the efficacy of antiemetic prophylaxis over multiple chemotherapy cycles. Areas Covered Here we discuss the use of antiemetic hydroxytryptamine type 3 (5-HT3) receptor and neurokinin (NK)-1 receptor antagonists for prevention of CINV, limiting our review to clinical trials in the context of multiple-cycle chemotherapy, with a focus on the NK-1 receptor antagonist rolapitant...
November 29, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27891523/5ht3-antagonists-versus-dexamethasone-in-the-prevention-of-ponv-in-patients-undergoing-laparoscopic-cholecystectomy-a-meta-analysis-of-rcts
#7
REVIEW
Chengmao Zhou, Yu Zhu, Zhen Liu, Lin Ruan
Background. 5HT3 antagonist, an antiemetic alternative to dexamethasone, is an effective drug for the prevention of postoperative nausea and vomiting (PONV). Methods. PubMed and The Cochrane Library (from inception to June 2016) were searched for relevant RCTs (randomized controlled trials). Results. Seven trials, totaling 682 patients, were included in this meta-analysis. This meta-analysis demonstrated that 5HT3 antagonist was as effective as dexamethasone in preventing PONV (RR, 1.12; 95% CI, [0.86, 1.45]; P = 0...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27888795/targeting-tachykinin-receptors-in-neuroblastoma
#8
Anton G Henssen, Andrea Odersky, Annabell Szymansky, Marleen Seiler, Kristina Althoff, Anneleen Beckers, Frank Speleman, Simon Schäfers, Katleen De Preter, Kathy Astrahanseff, Joachim Struck, Alexander Schramm, Angelika Eggert, Andreas Bergmann, Johannes H Schulte
Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy regimens is a promising approach to improve survival in these patients. TACR1 activation by substance P has been reported to be mitogenic in cancer cell lines. Tachykinin receptor (TACR1) antagonists are approved for clinical use as an antiemetic remedy since 2003. Tachykinin receptor inhibition has recently been shown to effectively reduce growth of several tumor types...
November 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27887932/assessing-national-provision-of-care-variability-in-bariatric-clinical-care-pathways
#9
Dana A Telem, Saniea F Majid, Kinga Powers, Eric DeMaria, John Morton, Daniel B Jones
BACKGROUND: The American Society for Metabolic and Bariatric Surgery (ASMBS) Quality Improvement and Patient Safety (QIPS) Committee hypothesized that collecting and sharing clinical pathways could provide a valuable resource to new and existing bariatric programs. OBJECTIVE: To shed light on the variability in practice patterns across the country by analyzing pathways. SETTING: United States Centers of Excellence METHODS: From June 2014 to April 2015, clinical pathways pertaining to preoperative, intraoperative, and postoperative management of bariatric patients were solicited from the ASMBS executive council (EC), QIPS committee members, and state chapter presidents...
August 3, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/27885469/nepa-a-fixed-oral-combination-of-netupitant-and-palonosetron-improves-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-over-multiple-cycles-of-chemotherapy-results-of-a-randomized-double-blind-phase-3-trial-versus-oral-palonosetron
#10
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona-Huerta, Vincent Hansen, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Hope Rugo
PURPOSE: Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. NEPA showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with oral PALO in a single chemotherapy cycle; maintenance of efficacy/safety over continuing cycles is the objective of this study...
November 24, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27880811/oral-ondansetron-versus-domperidone-for-acute-gastroenteritis-in-pediatric-emergency-departments-multicenter-double-blind-randomized-controlled-trial
#11
Federico Marchetti, Maurizio Bonati, Alessandra Maestro, Davide Zanon, Francesca Rovere, Alberto Arrighini, Egidio Barbi, Paolo Bertolani, Paolo Biban, Liviana Da Dalt, Andrea Guala, Elisa Mazzoni, Anna Pazzaglia, Paolo Francesco Perri, Antonino Reale, Salvatore Renna, Antonio Francesco Urbino, Enrico Valletta, Antonio Vitale, Tiziana Zangardi, Antonio Clavenna, Luca Ronfani
The use of antiemetics for vomiting in acute gastroenteritis in children is still a matter of debate. We conducted a double-blind randomized trial to evaluate whether a single oral dose of ondansetron vs domperidone or placebo improves outcomes in children with gastroenteritis. After failure of initial oral rehydration administration, children aged 1-6 years admitted for gastroenteritis to the pediatric emergency departments of 15 hospitals in Italy were randomized to receive one oral dose of ondansetron (0...
2016: PloS One
https://www.readbyqxmd.com/read/27873176/palonosetron-aprepitant-and-dexamethasone-for-prevention-of-nausea-and-vomiting-after-high-dose-melphalan-in-autologous-transplantation-for-multiple-myeloma-a-phase-ii-study
#12
Atsushi Isoda, Rie Saito, Fuminori Komatsu, Yuki Negishi, Noriyasu Oosawa, Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, Akihiro Manaka
Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous stem cell transplantation (ASCT). We evaluated the efficacy and safety of a triple antiemetic combination of palonosetron, aprepitant, and low-dose dexamethasone in 24 MM patients who received melphalan conditioning (100 mg/m(2) on days 1-2) before ASCT (on day 4). Intravenous palonosetron (0.75 mg on day 1), oral aprepitant (125 mg on day 1; 80 mg on days 2-4), and intravenous dexamethasone (6...
November 21, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27872331/systemic-hypersensitivity-to-fosaprepitant-a-report-of-two-cases
#13
Allison Baxley, Zoe Lee, Patrick Medina
Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection site reactions are the most common type of infusion reaction reported from fosaprepitant. At our institution, two separate patients have experienced systemic hypersensitivity reactions to their infusions of fosaprepitant. We report a review of the literature and the details of these reactions.
November 21, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27871585/optimal-epidural-analgesia-for-patients-diagnosed-as-having-gynecologic-cancer-undergoing-interstitial-brachytherapy
#14
Ashley K Amsbaugh, Mark J Amsbaugh, Moataz N El-Ghamry, Brian M Derhake
STUDY OBJECTIVE: To determine the optimal epidural analgesia for patients receiving interstitial brachytherapy (ISBT) for gynecologic cancers. DESIGN: Retrospective analysis. SETTING: Operating room and hospital ward. PATIENTS: Seventy-three patients diagnosed as having gynecologic cancer and undergoing ISBT. INTERVENTIONS: Twelve patients received ropivacaine alone, 14 patients received ropivacaine with fentanyl, and 45 patients received ropivacaine with hydromorphone by epidural infusion...
December 2016: Journal of Clinical Anesthesia
https://www.readbyqxmd.com/read/27871557/effect-of-adjunctive-dexmedetomidine-on-postoperative-intravenous-opioid-administration-in-patients-undergoing-thyroidectomy-in-an-ambulatory-setting
#15
Kristin Long, Joseph Ruiz, Spencer Kee, Alicia Kowalski, Farzin Goravanchi, Jeff Cerny, Katy French, Mike Hernandez, Nancy Perrier, Elizabeth Rebello
STUDY OBJECTIVE: Two of the most feared complications for patients undergoing thyroid surgery are pain and postoperative nausea and vomiting. Thyroidectomy is considered high risk for postoperative nausea and vomiting, and recent studies have looked at adjuncts to treat pain, limit narcotic use, "fast-track" the surgical process, and enhance recovery without compromising the patient's safety. One such perioperative medication of interest is dexmedetomidine (Dex), a centrally acting α-2 agonist that has been associated with reducing pain and postoperative opioid consumption...
December 2016: Journal of Clinical Anesthesia
https://www.readbyqxmd.com/read/27870735/combination-of-5-ht3-antagonist-and-dexamethasone-is-superior-to-5-ht3-antagonist-alone-for-ponv-prophylaxis-after-laparoscopic-surgeries-a-meta-analysis
#16
Anirban Som, Sulagna Bhattacharjee, Souvik Maitra, Mahesh K Arora, Dalim Kumar Baidya
INTRODUCTION: 5-Hydroxytryptamine type 3 (5-HT3) receptor antagonists are the most commonly used drugs for postoperative nausea vomiting (PONV) prophylaxis. Dexamethasone is another antiemetic with proven efficacy in reducing PONV. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the combination of dexamethasone and 5-HT3 antagonist versus a 5-HT3 antagonist alone as prophylaxis of PONV in laparoscopic surgical patients...
December 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27868231/aprepitant-in-pediatric-patients-using-moderate-and-highly-emetogenic-protocols-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#17
Lucas Miyake Okumura, Fernanda D' Athayde Rodrigues, Maria Angelica Pires Ferreira, Leila Beltrami Moreira
AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study's selection and data extraction...
November 20, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27861438/cardiotoxic-antiemetics-metoclopramide-and-domperidone-block-cardiac-voltage-gated-na-channels
#18
Carsten Stoetzer, Marc Voelker, Thorben Doll, Joerg Heineke, Florian Wegner, Andreas Leffler
BACKGROUND: Metoclopramide and domperidone are prokinetic and antiemetic substances often used in clinical practice. Although domperidone has a more favorable side effect profile and is considered the first-line agent, severe cardiac side effects were reported during the administration of both substances. Cardiac Na channels are common targets of therapeutics inducing cardiotoxicity. Therefore, the aim of this study was to investigate whether the differential cardiotoxicities of metoclopramide and domperidone correlate with the block of Na channels...
November 17, 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27837002/safety-of-domperidone-in-treating-nausea-associated-with-dihydroergotamine-infusion-and-headache
#19
Nathaniel M Robbins, Hiroyuki Ito, Melvin M Scheinman, Peter J Goadsby
OBJECTIVE: To determine the safety of domperidone in the treatment of nausea associated with dihydroergotamine (DHE) infusion and headache. METHODS: We audited our use of domperidone for the inpatient management of nausea, focusing on known safety concerns, particularly potential cardiac arrhythmias. RESULTS: We reviewed 103 consecutive admissions of 90 patients admitted for IV DHE by infusion. Most admissions were to treat chronic migraine with (n = 53) or without (n = 46) aura...
November 11, 2016: Neurology
https://www.readbyqxmd.com/read/27829428/aromatherapy-for-the-treatment-of-ponv-in-children-a-pilot-rct
#20
Mathew B Kiberd, Suzanne K Clarke, Jill Chorney, Brandon d'Eon, Stuart Wright
BACKGROUND: Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications of general anesthesia in pediatrics. Aromatherapy has been shown to be effective in treating PONV in adults. Given the encouraging results of the adult studies, we planned to determine feasibility of doing a large-scale study in the pediatric population. METHODS: Our group conducted a pilot randomized controlled trial examining the effect of aromatherapy on post-operative nausea and vomiting in patients 4-16 undergoing ambulatory surgery at a single center...
November 9, 2016: BMC Complementary and Alternative Medicine
keyword
keyword
79588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"